Many new anticancer treatments are molecular targeted agents and only benefit a subgroup of patients within a histologically defined cancer Heterogeneity of treatment effects requires development of ...
The identification of subgroups of patients from randomized clinical trials that are of specific interest for guiding clinical decisions can be an attractive idea; however, since such trials are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback